Turnover—
EBIT margin—
Net result€-427k-140.0%
Working capital€347k+7.1%
Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of Neohla Bio is 0.4% (very low). The 2025 annual accounts show equity of €347k and a net result of €-427k. The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 2 annual accounts.
Financials
FY 2025
€347k
equity
Turnover—
Net result€-427kHealth55/100 · Fair
See full annual accounts
People & board
No director data processed yet.
To directors Publicationslatest 17-12-2025
13
publications in the State GazetteDischarge granted to the boardAll publications & acts Network & structure
3
connected companiesSee network & structure
Connections
3 connected companiesTrust signals
3 signalsMore than 3 years active
Founded in 2023 — past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad.
Administratively compliant
No FOD Economie strikeouts (UBO, accounts, address, activity).
Administrative Flags
0 events
No administrative flags
Bankruptcy probability (12 mo)
Checked model v1 · free for everyone0.4%
Very low
0%0,5%1,5%4%10%≥25%
Lower-risk legal form
−Young company
+Lower-failure-rate sector
−
Statistical estimate based on public sources — not credit advice nor a finding of fact. How do we compute this?
Company registry (CBE)
Crossroads BankActivities
Speur- en ontwikkelingswerk op biotechnologisch gebied72101Speur- en ontwikkelingswerk op biotechnologisch gebied72110
Primary activity highlighted.
Names & trade names
| Legal nameNL | Neohla Bio |
Registered office
Uitbreidingstraat 66 bus 31
2600 Antwerpen, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.